7081.KL(7081.KL)
7081.KL
Pharmaniaga Berhad is a Malaysian healthcare company specializing in the distribution of pharmaceutical products and medical supplies across Southeast Asia. With a strong foothold in Malaysia and expanding operations in Indonesia, the company leverages its extensive distribution network and strategic partnerships to drive revenue growth in a competitive market.
Pharmaniaga generates revenue primarily through the wholesale distribution of pharmaceuticals and medical supplies to hospitals, clinics, and pharmacies. The company benefits from strong relationships with key suppliers and has established a reputation for reliability in delivery and quality, which enhances its pricing power.
Changes in government healthcare spending in Malaysia and Indonesia
Regulatory approvals for new pharmaceutical products
Fluctuations in raw material costs affecting margins
Expansion of distribution contracts with major healthcare providers
Regulatory changes affecting pharmaceutical pricing and distribution practices
Technological disruption in supply chain management and distribution
Increased competition from local and international pharmaceutical distributors
Potential market entry of large multinational corporations with greater resources
High debt levels may lead to liquidity issues if cash flows do not improve
Low current ratio (0.92) indicates potential short-term liquidity concerns
moderate - The company's performance is somewhat linked to GDP growth and consumer spending, as healthcare spending tends to be more stable but can be influenced by economic conditions.
Rising interest rates could increase financing costs for Pharmaniaga, impacting its debt servicing due to a Debt/Equity ratio of 1.72, which may also affect valuation multiples as investors reassess risk.
minimal - The company is not heavily reliant on credit for its operations, but its high debt levels could pose risks if credit conditions tighten.
value - Investors may be attracted to the stock due to its low Price/Sales ratio of 0.4x, indicating potential undervaluation.
moderate - The stock has shown a 1-Year return of 72.4%, indicating some volatility but also strong recovery potential.